Literature DB >> 33552949

Effect of Tumor Size on Long-Term Survival After Resection for Solitary Intrahepatic Cholangiocarcinoma.

Junjie Kong1,2, Yukun Cao1,2, Jiawei Chai3, Xihan Liu4, Cunhu Lin5, Jianping Wang1,2, Jun Liu1,2.   

Abstract

BACKGROUND: The relationship between tumor size and survival in intrahepatic cholangiocarcinoma (ICC) is still controversial. This study aimed to evaluate the prognostic ability of tumor size for solitary ICC after resection and explore optimal cut-off values in different subgroups.
METHODS: Patients with solitary ICC who underwent liver resection from the Surveillance, Epidemiology, and End Results Program and Shandong Provincial Hospital were retrospectively analyzed. Kaplan-Meier and Cox regression analysis were used to assess the prognostic ability of tumor size. The log-rank test was used to determine the optimal cut-off values, and a minimum P was regarded as the optimal one in different subgroups.
RESULTS: Large tumor size groups had worse overall survival (OS) than small tumor size groups. Cox regression analysis suggested that tumor size was an independent prognostic factor for OS for solitary ICC after resection. Subgroup analysis showed tumor size was associated with OS for both solitary ICC with and without vascular invasion (VI). Furthermore, the optimal cut-off values for solitary ICC with and without VI were found to be 8 and 3 cm, respectively, which could divide the patients into two groups with significant differences in OS.
CONCLUSION: Tumor size was an independent prognostic factor for solitary ICC after resection. The existing American Joint Committee on Cancer (AJCC) staging system could be improved if the cut-off value of the T1 stage was changed to 8 cm and if the T2 stage incorporated a tumor size with a cut-off value of 3 cm. Further studies with more cases are needed to validate these findings.
Copyright © 2021 Kong, Cao, Chai, Liu, Lin, Wang and Liu.

Entities:  

Keywords:  SEER; intrahepatic cholangiocarcinoma; overall survival; resection; solitary; tumor size

Year:  2021        PMID: 33552949      PMCID: PMC7859518          DOI: 10.3389/fonc.2020.559911

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  31 in total

1.  A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "metro-ticket" paradigm.

Authors:  Kota Sahara; Diamantis I Tsilimigras; Rittal Mehta; Fabio Bagante; Alfredo Guglielmi; Luca Aldrighetti; Sorin Alexandrescu; Hugo P Marques; Feng Shen; Bas G Koerkamp; Itaru Endo; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2019-04-19       Impact factor: 3.454

2.  The risk factors and prognostic factors of intrahepatic cholangiocarcinoma.

Authors:  Xi-Hsuan Lin; Jiing-Chyuan Luo
Journal:  J Chin Med Assoc       Date:  2017-01-12       Impact factor: 2.743

3.  The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer.

Authors:  Brian C Gulack; Chi-Fu Jeffrey Yang; Paul J Speicher; James M Meza; Lin Gu; Xiaofei Wang; Thomas A D'Amico; Matthew G Hartwig; Mark F Berry
Journal:  Lung Cancer       Date:  2015-10-14       Impact factor: 5.705

4.  Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Takahito Nakagawa; Toshiya Kamiyama; Nobuaki Kurauchi; Michiaki Matsushita; Kazuaki Nakanishi; Hirofumi Kamachi; Takeaki Kudo; Satoru Todo
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

5.  Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.

Authors:  Yuexiang Liang; Lijie Liu; Xiaoming Xie; Liping Xia; Jin Meng; Ronghua Xu; Donglei He
Journal:  J Surg Res       Date:  2019-03-23       Impact factor: 2.192

6.  Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.

Authors:  Tatsuya Orimo; Toshiya Kamiyama; Tomoko Mitsuhashi; Hirofumi Kamachi; Hideki Yokoo; Kenji Wakayama; Shingo Shimada; Akihisa Nagatsu; Akinobu Taketomi
Journal:  J Gastroenterol       Date:  2018-05-02       Impact factor: 7.527

7.  A proposed staging system for intrahepatic cholangiocarcinoma.

Authors:  Hari Nathan; Thomas A Aloia; Jean-Nicolas Vauthey; Eddie K Abdalla; Andrew X Zhu; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2008-11-06       Impact factor: 5.344

Review 8.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management.

Authors:  Han Zhang; Tian Yang; Mengchao Wu; Feng Shen
Journal:  Cancer Lett       Date:  2015-09-25       Impact factor: 8.679

9.  The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.

Authors:  Bimal Bhindi; R Houston Thompson; Christine M Lohse; Ross J Mason; Igor Frank; Brian A Costello; Aaron M Potretzke; Robert P Hartman; Theodora A Potretzke; Stephen A Boorjian; John C Cheville; Bradley C Leibovich
Journal:  Eur Urol       Date:  2018-07-13       Impact factor: 20.096

10.  Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan.

Authors:  Yoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu Nakashima
Journal:  Cancer       Date:  2015-10-02       Impact factor: 6.860

View more
  2 in total

1.  Diffusion-weighted imaging as an imaging biomarker for assessing survival of patients with intrahepatic mass-forming cholangiocarcinoma.

Authors:  Julaluck Promsorn; Kulyada Eurboonyanun; Payia Chadbunchachai; Chaiwat Apivatanasiri; Kosin Wirasorn; Jarin Chindaprasirt; Aumkhae Sookprasert; Mukesh Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2022-06-15

2.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.